Sanofi's Dual Influenza-COVID-19 Vaccines Receive FDA Fast Track Designation For Individuals 50 Years Of Age And Older
Sanofi's Dual Influenza-COVID-19 Vaccines Receive FDA Fast Track Designation For Individuals 50 Years Of Age And Older
賽諾菲安萬特的雙重流感-新冠疫苗獲得FDA對50歲及以上人群的快速通道認證
Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
兩種組合疫苗候選者獲得美國快速通道認證，用於預防流感和新冠病毒
- First non-mRNA combination vaccine candidates that include two already licensed vaccines to prevent influenza and COVID-19 infections
- Two phase 1/2 clinical studies are ongoing to evaluate the safety profile and immune response induced by the combination vaccine candidates
- 首款非mRNA組合疫苗候選者，包括兩種已獲得許可的疫苗，用於預防流感和新冠病毒感染
- 正在進行兩項1/2期臨床研究，以評估組合疫苗候選者的安全性和免疫反應
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間